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Abstract
Background: Although Caesarean scar pregnancy (CSP) is rare, it can cause life-threatening complications. The
increasing rate of Cesarean delivery plus rapid development of in vitro fertilization-embryo transfer (IVF-ET) may
increase the occurrence of CSP as well as the ratio of heterotopic CSP (HCSP)/CSP. Therefore, early diagnosis and
management of CSP are necessary to avoid serious complications. And the purpose of this article is to evaluate the
importance and feasibility of the first-trimester diagnosis and management of CSP after IVF-ET.
Methods: All the 12 cases were secondary infertility patients who had a history of Cesarean section and underwent
IVF-ET in our reproductive center. All cases with CSP were diagnosed using transvaginal color Doppler sonography
(TVS). Medical, surgical and expectant managements were implemented, and the management results were traced.
Results: Patients with CSP (n = 12) were diagnosed from January 2011 to April 2015, 6 (50 %) of which were HCSP.
The prevalence of CSP was 1:1688 pregnancies. The gestational age ranged from 5 + 3 to 7 + 4 weeks in all CSP,
and from 5 + 6 to 7 + 4 weeks in HCSP at diagnosis. Five patients received successful surgical treatment. The
success rate of medical and expectant management was 50 % (1/2) and 100 % (5/5), respectively. One patient with
failed medical management needed an emergency laparotomy to evacuate CSP. The uterus was preserved in all
12 patients.
Conclusions: The Caesarean section and IVF-ET may increase the ratio of HCSP/CSP. TVS is a noninvasive and
effective tool for use in diagnosing CSP. CSP should be carefully excluded in patients who have had a history of
Caesarean section. Early diagnosis of CSP in the first trimester may contribute towards the preservation of uterus as
well as intrauterine pregnancy (IUP) in HCSP.
Keywords: Cesarean scar pregnancy, Heterotopic cesarean scar pregnancy, First-trimester, Transvaginal sonography,
Diagnosis, Management, In vitro fertilization-embryo transfer
Background
Caesarean scar pregnancy (CSP) is defined as an ectopic
pregnancy (EP) implanted in the myometrium of a previ-
ous Cesarean section scar [1]. Ever since the first case of
CSP was reported by Larsen and Solomon in 1978 [2],
there has been increasing attention paid to this rare
condition. Although many hypotheses have been pro-
posed to explain the mechanism of CSP, its etiology is
still unclear. One probable theory is the conceptus
might migrate through a microscopic dehiscent tract
from the endometrial canal to the scar tissue [3, 4].
The predisposing risk factors include uterine trauma,
Caesarean section, myomectomy, in-vitro fertilization-
embryo transfer (IVF-ET), manual removal of pla-
centa, adenomyosis, etc. [5]. IVF-ET could be a sole risk
factor even without any previous uterine surgery [6].
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The incidence of CSP is extremely low, and has been
estimated from 1:2216 to 1:1800 [3, 7, 8]. Although this
entity is extremely rare, it can cause life-threatening
complications such as uterine rupture and catastrophic
hemorrhage which may relate to maternal and fetal mor-
bidity and mortality, even at the early stage of gestation
[1]. The rate of Cesarean delivery increases continuously
over the years [3, 9]. Particularly in China, almost 50 %
infants are delivered by Cesarean section, which may
increase the occurrence of CSP [10, 11]. In addition,
with the widespread use of IVF, the incidence of HP has
increased to 1 %, which is estimated from 1:50,000 to
1:10,000 spontaneously [12, 13]. Therefore, the occur-
rence of heterotopic CSP (HCSP), one of the rarest
forms of EP, is also increasing [14]. All of the above
necessitate the early diagnosis and treatment of this
special kind of EP to avoid serious complications and
preserve patients’ fertility.
However, there has been no study focusing on the
first-trimester diagnosis and management of CSP in IVF
patients currently, and due to its rarity, no universal
treatment guideline has been established until now.
Herein, we evaluated 12 cases of pregnancies implanted
into the previous Cesarean section scar after IVF-ET
procedure in our unit over a 4-year period. All patients
were detected by transvaginal sonography (TVS) and
managed in the first trimester. We present our ex-
perience and evaluate the importance and feasibility
of the first-trimester diagnosis and management of
CSP after IVF-ET.
Methods
From January 2011 to April 2015, 12 cases of CSP were
diagnosed in the Reproductive and Genetic hospital of
Citic-Xiangya. All 12 cases were secondary infertility pa-
tients who had a history of Cesarean section and had
undergone IVF-ET at our reproductive center. The clin-
ical data of the 12 patients were analyzed retrospectively
in this study.
A routine blood test for serum beta human chorionic
globulin (β-hCG) was performed on Day 14 after IVF-
ET, and a routine TVS scan was scheduled on Day 28
post IVF-ET to examine the viability and location of
pregnancies. GE VOLUSON E8/730 (GE Tech Co., Ltd.,
New York, America) equipped with a 5–9 MHz vaginal
color Doppler probe was used. If patients complained of
abdominal pain and/or vaginal bleeding, TVS examin-
ation would be arranged soon.
When the following sonographic criteria were all met,
the diagnosis of CSP was made [3, 12, 13, 15–17]: (1)
the uterine cavity was empty; (2) empty cervical canal
without a gestational sac; (3) a gestational sac showing
the ‘double ring sign’ with or without cardiac activity
located anteriorly at the level of the internal os; (4) a
mixed mass or a clear gestational sac embedded at the
lower uterine segment, within the myometrium and the
fibrous tissue of the previous Cesarean section scar, and
it was separated from the endometrial cavity or fallopian
tube; (5) a visible myometrial defect between the bladder
and the sac and a discontinuity in the anterior wall of
the uterus being demonstrated on a sagittal view of the
uterus running through the amniotic sac; (6) the pres-
ence of increased peritrophoblastic or periplacental-
vascularity around the location of previous Cesarean
section scar on color Doppler examination; (7) negative
‘sliding organs sign’, which refers to the position of gesta-
tional sac could not be changed by gentle pressure
applied by the transvaginal probe (Fig. 1). When an
intrauterine pregnancy (IUP) coexisted with another
pregnancy which satisfied all except (1) criteria men-
tioned above, the diagnosis of HCSP was made. The
myometrial thickness between CSP and the bladder was
measured in the meantime (Fig. 2).
The management plans were formulated according to
the size, gestational age (GA), peritrophoblastic vascular-
ity and viability of CSP. Clinical symptoms, myometrial
thickness, as well as patients’ wishes, were also taken
into consideration. The expectant treatment might be
considered if the women with minimal clinical symp-
toms and there is ultrasound demonstrated non-viable
pregnancies. The medical treatment was appropriate
when the patient was pain free, haemodynamically stable
with unruptured CSP and those with signs of abnormal
placentation involving the myometrium [15, 18]. The
surgical treatment was offered to women who had failed
non-surgical treatment or experienced heavy bleeding.
All patients were informed of the severity of CSP and
Fig. 1 Ultrasound findings of a typical CSP. Longitudinal section of
the uterus showing a 6 + 3 weeks with cardiac activity gestational
sac (Case 1; crown–rump length:3.6 mm) implanted into a previous
Cesarean section scar and protruding towards the urinary bladder
with strong peripheral color doppler signals
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gave informed consent before treatment. Conservative
treatment was the primary choice since all patients had
a desire for continued fertility. This study was reviewed
and approved by the institutional review board of the
Reproductive and Genetic hospital of Citic- Xiangya.
In this study, surgical evacuation of CSP included
hysteroscopy, TVS guidance dilatation and curettage
(D&C). Laparotomy with wedge excision of CSP was
employed as a remedy in one case due to a large
amount of vaginal bleeding after methotrexate (MTX)
treatment. Systemic MTX (50 mg/cm2) and uterine
artery embolization (UAE) were used as a pretreat-
ment in some cases. High intensity focused ultra-
sound (HIFU) combined with suction curettage were
used on one patient. And HIFU treatment was carried
out using the Haifu JC-200 focused ultrasound tumor
therapeutic system (Chongqing Haifu Tech Co., Ltd.,
Chongqing, China). In the HCSP cases, if the ectopic
CSP was an empty gestational sac, or with no viable
embryo, the patients would be treated expectantly; if
the CSP had detectable cardiac activity, selective embryo
reduction in situ with sonographic guidance would be
chosen, and potassium chloride (0.1–0.2 nmol) intracar-
diac injection was used. β-hCG testing and TVS scan were
performed every 3–5 days in CSP patients during
hospitalization and weekly thereafter, until β-hCG < 5
mIU/mL and no peritrophoblastic blood flow could be
detected. In heterotopic cases, a TVS scan was performed
every 3–5 days to confirm the treatment effects of CSP
and observe the IUP during hospitalization and weekly
thereafter. If expectant management or selective embryo
reduction was applied, the retained mass of CSP would be
assessed.
Results
Over a period of four years, 12 secondary infertility
patients were found to have pregnancies implanted into
a previous lower segment Cesarean section scar in our
hospital, and 6 (50 %) of which were HCSP cases. The
incidence of CSP was 1:1688 (12/20256) and HCSP was
1:3376 (6/20256) in this study. The maternal age (MA)
of the 12 patients was 33.75 (range, 27–41) years. All the
12 patients had one previous Cesarean section and the
time interval between last Cesarean section and the
current CSP ranged from 3–17 years. An incision lacuna
had been detected in 4 patients under TVS before IVF.
The infertility factors included tubal factors, ovulatory
disorders, an abnormal pregnancy history, endometriosis
and male factors. IVF procedures had been conducted in
all the 12 patients, IVF in 7 patients, ICSI in 4 patients,
IVF plus ICSI in 1 patient. Two to three high quality
fresh or frozen embryos had been transferred into each
patient and a total of 25 embryos had been transferred,
9 of gradeI, 16 of gradeII. The mean Day 14 β-hCG of
CSP (except HCSP) after transfer was 308.15 (range,
165.3–483.8) mIU/mL, and 1012.45 (range, 558.9–1656)
mIU/mL of HCSP. Eight patients complained of vaginal
bleeding, and 4 of the patients suffered abdominal pain
in addition to this. Two patients complained of only
abdominal pain, but there were no symptoms in the
remaining 2 patients (Table 1).
All of the 12 cases with CSP were diagnosed in the
first trimester by TVS. The GA ranged from 5 + 3 to
7 + 4 weeks in all CSP cases, from 5 + 6 to 7 + 4 weeks in
HCSP at diagnosis. On ultrasound examination, 6 gesta-
tional sacs had fetal pole (range, 2.0–5.4 mm) and cardiac
activity showed in 4 of these cases. The myometrial thick-
ness between CSP and bladder ranged from 2.7 to
7.4 mm. Five (42 %) patients were initially treated surgi-
cally, two medically (16 %), and five expectantly (42 %).
In the surgical group, MTX, UAE and HIFU ablation
were used to prevent massive hemorrhage during the
surgical procedures in Case 3, Case 5 and Case 6. Case 6
received one session of HIFU ablation under conscious
sedation, and suction curettage under hysteroscopic
guidance was performed 2 days later. No product of
conception was retained in any of the patients after
surgical management. In the medical group, the success
rate was 50 %. Case 11 who had a HCSP was success-
fully treated with TVS guidance local KCL injection to
reduce the live embryo of CSP. However, the IUP termi-
nated at 14 weeks and TVS guidance D&C was then
implemented in Case 11. Case 1, who was initially
treated with TVS guidance local MTX plus systemic
MTX suffered heavy vaginal bleeding (>1000 mL) as well
as abdominal pain, so was classified as failed, and an
emergency laparotomy with a wedge excision of CSP
was performed at 6 weeks to evacuate the CSP.
Fig. 2 Ultrasound findings of a HCSP. Longitudinal section of the
uterus showing the coexistance of an intrauterine pregnancy with a
live embryo (F2, crown–rump length:11.1 mm) and a gestational sac
with a dead embryo (F1, crown–rump length:3 mm) implanted into
the lower segment Cesarean section scar in Case 9 at 7 + 4 weeks
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2 II,II 10.2 281 - -
2 33 22.7 No G2,P1 1 9 tubal + male No 1 IVF,
D3transfer
2 I,II 20.2 367.3 + -
3 39 20.02 No G4,P2 1 17 tubal Yes 2 IVF, D3 +
D5transfer
2 I,II 11.1 235.5 + -
4 41 24.97 No G2,P1 1 9 tubal + male No 2 ICSI,FET 2 II,II 10.3 483.8 + +




2 II,II 13.8 316 + +
6 33 21.09 No G1,P1 1 5 male No 2 ICSI,
D3transfer
2 II,II 16.3 165.3 + -
7 34 20.2 No G2,P1 1 10 tubal No 1 IVF + ICSI,
D3transfer
3 I(1)a, II(2)a 14.7 935.2 + +
8 32 18.21 No G4,P1 1 5 tubal No 1 IVF,
D3transfer
2 I,I 14.2 980.4 - +
9 38 20.17 No G4,P1 1 10 tubal + male No 1 ICSI,
D3transfer
2 II,II 12.1 843.2 - +





2 I,I 13.2 558.9 - -
11 36 21.83 No G4,P1 1 8 tubal Yes 1 IVF,
D3transfer
2 I,II 13.6 1101 + -
12 34 23.3 No G4,P1 1 8 tubal No 1 IVF,FET 2 I,II 11.2 1656 + +
BMI body mass index, C/S cesarean section, IVF in-vitro fertilization, LSCS lower segment Cesarean sections, D day, ICSI intracytoplasmic sperm injection, FET frozen embryo transfer, β-hCG beta-human chorionic gonadotropin













In the expectant group, the CSP was an empty sac in
Case 8 and Case 12, only with a yolk sac in Case 7 and
Case 10, a fetal pole measured 3 mm without cardiac
activity in Case 9 upon diagnosis. Embryo development
cessation of CSP was diagnosed by subsequent TVS
detection and expectant management was chosen in
these 5 patients with HCSP. Two babies were born in
this group. Case 7 experienced a large amount of vaginal
bleeding due to complete placenta previa, and a healthy
boy weighing 2600 g was delivered by an emergency
Caesarean section at 35 weeks’ gestation. Surgical explor-
ation of the scar found an amorphous mass (21 × 14 mm)
which was removed intraoperatively, and deciduous
tissues were found during the pathological examination.
The development of IUP was uneventful in Case 10 and a
healthy girl, weighing 2900 g, was delivered by Caesarean
section at 36 weeks’ gestation due to the premature
rupture of membranes. And the scar mass disappeared at
22 weeks’ gestation in Case 10.
TVS guidance D&C was performed in Case 8 because
of IUP termination at 13 weeks’ gestation. Case 9 experi-
enced a second trimester abortion (6 months’ gestation).
The IUP of Case 12 remained viable and progressed
uneventfully until the time of writing (18 weeks’ gestation)
and there was still a detectable ectopic mass (32 × 27 mm)
under TVS. Although full-term birth was not achieved in
Case 8, Case 9 and Case 12, the management of these
three cases were classified as successful due to the
particularity of HCSP. Therefore, the success rate was
100 % (5/5) in the expectant group.
In the patients who were successfully treated, the β-
hCG resolution time was between 26 and 52 days with
the exception of HCSP. And the disappearance time of
peritrophoblastic flow after treatment ranged from 30 to
118 days (mean 61 days), from 44 to 118 days of HCSP
patients (mean 76 days). And the uterus was preserved
in all the 12 patients (Table 2).
Discussions
The incidence of CSP was 1:1688 in this study, which
seemed higher than previous reports [3, 7]. Moreover,
the ratio of HCSP/CSP increased to 50 %, which was
much higher than spontaneous condition, suggesting
IVF could be a contributor to the occurrence of CSP
and could greatly increase the likelihood of HCSP. A
question may be raised why CSP occurred in IVF-ET,
since the embryos were transferred directly into the
uterine cavity. We could also ask whether there is an
association between CSP and IVF-ET technology. The
occurrence of CSP might be explained by the ectopic
tract which has been previously mentioned [3, 4]. And it
was reported that frozen cycles were associated with
lower rates of EP compared with fresh cycles [19];
Frozen-thawed Day 5 blastocyst transfer was associated
with a lower EP rate than frozen-thawed Day 3 transfer
and fresh transfer [20]; Higher EP rates in GnRH agonist
triggered cycles relative to hCG triggered cycles [21];
The endometrial thickness was thinner in patients with
an EP [22], and so on. Then, whether fresh and frozen
cycles, IVF and ICSI, Day 3 and Day 5 transfer, and the
classification of embryo quality, etc. have different effects
on the occurence of CSP? Although there is still no
study focusing on the relation between CSP and IVF-ET
technology, we are not able to analyze it here due to the
small number of patients. A larger sample is needed for
further study.
Many reports have expressed the notion that CSP
cases are more likely to happen after multiple Cesarean
sections [3, 5, 7]. But all the 12 patients had experienced
only one Cesarean section due to the Family Planning
Policy in China. Accordingly, the correlation between
multiple Cesarean sections and CSP cannot be discussed
under such circumstances in this study.
Vaginal bleeding and mild to moderate abdominal pain
were the most common symptoms in the 12 patients,
and 33.3 % (4/12) patients presented both of these. But
the manifestations were not specific. There were two
cases without any symptoms which were diagnosed by
routine Day 28 TVS examination. Therefore, the lack of
symptoms does not mean CSP is necessarily avoided.
Previous studies have suggested that most cases of HCSP
were without any symptoms and diagnosed by routine
first-trimester sonography [23, 24]. But in this study,
83.3 % (5/6) patients with HSCP were diagnosed based
on clinical symptoms. And the difference means a large
sample is needed for further study.
An effort to diagnose CSP early is always made in
women with a history of Cesarean section. High-
resolution TVS appears to be the best diagnostic tool,
as it is highly efficient in the diagnosis of CSP. The size,
shape and position of CSP can be detected via a two
dimensional TVS scan. In addition, the blood flow sig-
nals around CSP and fetal cardiac activity can be visual-
ized through the color doppler flow index (CDFI).
When profuse vascularity shows around the location of
CSP, the patients should be informed of the risk of uter-
ine rupture [3], and corresponding treatment should be
applied immediately. Moreover, CSP should be differen-
tially diagnosed with low IUP, cervical pregnancy and
miscarriage. It is relatively simple to differentiate them
early in pregnancy, but as the pregnancy progresses,
the distinction becomes more difficult. All the 12 pa-
tients were diagnosed in the first trimester (range, 5 + 3
to 7 + 4 weeks), the early diagnostic time was attributed
to the utilization of TVS and routine TVS examination
after IVF-ET. But there were 4 patients who were diag-
nosed later than Day 28 due to having received some
clinical treatments to deal with the vaginal bleeding
Ouyang et al. Reproductive Biology and Endocrinology  (2015) 13:126 Page 5 of 9
Table 2 Clinical diagnosis and treatment of 12 patients with first trimester Cesarean scar pregnancies





















1 6 + 3 CSP 22 × 12 3.6 Viable 2.9 TVS guidance
local MTX +
Systemic MTX
No - - Laparotomy with wedge excision
of CSP at 6 W+ due to massive
vaginal bleeding and abdominal
pain after MTX treatment
2 5 + 3 CSP 6 × 5 no Non-viable 4.7 Hysteroscopy Yes 38 42 Cured, no attempt at another pregnancy
3 6 + 2 CSP 18 × 14 2 Viable 4.5 Systemic MTX +
TVS guidance D&C
Yes 52 49 Cured, waiting for another IVF treatment
4 5 + 6 CSP 16 × 10 no Non-viable 3.7 Hysteroscopy Yes 32 41 Cured, no attempt at another pregnancy
5 7 + 0 CSP 27 × 17 5.4 Viable 3.3 UAE +
Hysteroscopy
Yes 44 57 Cured, no attempt at another pregnancy




Yes 26 30 Cured, no attempt at another pregnancy
7 6 + 5 Heterotopic 16 × 7 no Non-viable 5.9 Expectant Yes - 77 Cesarean section due to massive
hemorrhage caused by complete
placenta previa at 35 W+,ectopic
mass (21 × 14 mm) was removed
at the same time, and a healthy
boy weighing 2.6 kg was born
8 5 + 6 Heterotopic 19 × 6 no Non-viable 2.7 Expectant Yes - 52 TVS guidance D&C due to IUP
termination at 13 W+
9 7 + 4 Heterotopic 20 × 12 3 Non-viable 5.2 Expectant Yes - 96 Second trimester abortion (6 months’
gestation) of IUP
10 6 + 3 Heterotopic 4 × 3 no Non-viable 7.4 Expectant Yes - 69 Cesarean section due to premature
rupture of membranes at 36 W+,
a healthy girl weighing 2.9 kg was
born; Scar mass disappeared at 22 W+
11 6 + 3 Heterotopic 39 × 8 3.4 Viable 4.2 TVS guidance
local KCL
Yes - 44 TVS guidance D&C due to IUP
termination at 14 W+
12 7 + 1 Heterotopic 27 × 10 no Non-viable 4.1 Expectant Yes - 118 IUP was 18 W+ gestation at the time
of writing; Retained ectopic mass
(32 × 27 mm)
CSP Cesarean scar pregnancy, CRL crown—rump length, TVS transvaginal ultrasound guidance, MTX methotrexate, D&C dilatation and curettage, UAE uterine artery embolization, HIFU high intensity focused ultrasound,













and/or abdominal pain, and therefore postponed their
TVS scan time.
TVS plus Day 14 β-hCG are important diagnostic
methods after IVF-ET. And Day 14 β-hCG is useful in
predicting the pregnancy outcome. In this study, the
level of Day 14 β-hCG in CSP was similar to a normal
single IUP, and the level in HCSP was similar with twin
IUP or HP. Therefore, Day 14 β-hCG alone has little
value in determining the location of CSP. When the level
of Day 14 β-hCG is high, it is necessary to exclude a
coexisting EP after the diagnosis of IUP has already been
made. And CSP should be carefully excluded in patients
with a history of Caesarean section.
The majority of Cesarean scars are well-healed, but
visible deficiency may be detected in a small number of
women due to fibrosis cause poor vascularity of the lower
uterine segment which in turn affects the scar postopera-
tive healing [7]. We need to determine whether it is neces-
sary to repair the incision lacuna. Surgical repair before
the next conception was recommended by some authors
[25, 26]. However, other authors hold a contrary opinion
that surgical repair itself was a trauma to patients and it
might not prevent the occurrence of uterine rupture in
the subsequent pregnancy [3, 27]. Incision lacuna was de-
tected in 5 patients and the Cesarean scars were well-
healed in the other 7 cases in this study, suggesting CSP
might also occur in well-healed Cesarean scars, therefore,
the necessity of surgical repair was questionable.
The previous literature has shown that complications
such as miscarriage, EP, abruptio placentae, placenta pre-
via and placenta accreta are more likely to happen in
women with a history of Cesarean section [28]. In this
study, there were two babies born, however, one with
complete placenta previa and the other with premature
rupture of membranes. And 66.67 % (8/12) cases of CSP
ended in spontaneous first-trimester miscarriages which
seemed higher than the findings of a previous study [7].
The first-trimester miscarriage rate could be higher if all
cases were managed expectantly. However, the mean
MA was 33.75 years which might be another contributor
to this high rate.
Early diagnosis makes early treatment possible which
may reduce complications and improve the treatment
success rate. All patients in our center have fertility
requirements, so it is important to take relatively conser-
vative approaches to preserve the uterus. However, with
limited experience of CSP in the first trimester, it is diffi-
cult to decide on optimal management. There were 2
cases that were managed medically, and the success rate
was 50 %. Local + system MTX treatment failed in Case
1 and expedient laparotomy had to be implemented due
to extensive vaginal bleeding. And it was the only one
case treated through laparotomy in this study. Stevens
EE [29] had reported a case with massive haemorrhage
postoperative after the treatment of a combination of
local and system MTX injection. However, most previ-
ous studies regarded MTX especially local MTX injec-
tion as an effective management technique [30, 31].
The success rate of the medical group in this study
was not representative due to the small sample involved.
There are risks of profuse haemorrhage and uterine
rupture when only treated medically [29], thus many
doctors prefer combined treatment. In fact, some cases
in the surgical group were combined with medical ther-
apy in this study.
The patients of the surgical group were all successfully
treated transcervically. MTX and UAE were effectively
used to prevent intraoperative bleeding before the oper-
ation. Owing to the strong demands of patient, HIFU
was tentatively applied in Case 6. HIFU is a relatively
new technique which has been used in recent years. It
can convert acoustic waves to thermal energy at the
focal point where the temperature increases over 65 °C
and coagulative necrosis occurs. It has been demon-
strated that it can be used to treat various diseases
successfully, such as breast tumors, hepatocellular car-
cinomas, bone malignancy, pancreatic cancers [32–35],
uterine fibroids [35, 36], adenomyosis [37] and so on.
Over the past few years, there have been some studies
focusing on the treatment of CSP by this non-invasive
technique, which consider HIFU to be an effective
method [38–40]. In addition, it can apparently decrease
the risk of intraoperative hemorrhage [40]. The applica-
tion of HIFU in this study was successful, and no obvi-
ous complications were observed. There were relatively
short time for β-hCG to reach normal level and peritro-
phoblastic flow to disappear after HIFU ablation. And
the same method was also successful in 35 patients in
the Xiaogang Zhu’s [38] study. But investigations with a
larger sample size are necessary to further confirm its ef-
fectiveness in treating CSP.
The ratio of HCSP/CSP was quite high in this study.
We considered the reason to be partly attributable to
the application of IVF-ET, and partly attributable to co-
incidence. It is troublesome to deal with CSP, not to
mention whilst simultaneously protecting the IUP. Ex-
pectant treatment is not encouraged due to the cata-
strophic risk of CSP [3, 7]. Jurkovic D. [7] has reported 2
failed cases in 3 patients who were treated expectantly.
There were 5 (41.67 %) patients with HCSP managed ex-
pectantly in this study, the IUP of which went through
the first trimester smoothly under close observation, and
consequently, two babies were born. It suggests that
expectant management under close observation may be
an appropriate choice when the development of the CSP
in HCSP was confirmed to have a termination. And this
opinion had been advocated by some researchers [41, 42].
However, it didn’t mean that expectant management
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could be used in all HCSP, when fetal cardiac activity was
detected, just as was the case in Case 11 in this study, the
selective embryo reduction in situ may be appropriate,
and it had been demonstrated in some of the previous
literatures [43, 44].
Conclusions
In summary, CSP is rare but can cause life-threatening
complications. And the Caesarean section and IVF-ET
may increase the ratio of HCSP/CSP. When the diagno-
sis and treatment of CSP are made in the first trimester,
the prognosis is better and the fertility of most patients
as well as the IUP of HCSP is more likely to be
preserved.
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